CRISPR-Cas9 como ferramenta de terapia génica na doença de Machado-Joseph: silenciamento da ATXN3 e correção da expansão CAG
Year: 2019
Type: dissertation
Abstract: Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3, is a neurodegenerative disorder considered to be the most common form of autosomal dominantly-inherited ataxia in the world. It is a rare disorder, although it has a significative prevalence in some regions of Portugal, especially in the archipelago of Azores. MJD symptoms include a loss of motor coordination and other neurological signs, with the cerebellum being the most affected brain region. MJD arises from an abnormal CAG trinucleotide expansion within the exon 10 of the human ATXN3 gene, which encodes for a protein named ataxin-3 (atxn-3), that bears an aberrant polyglutamine (polyQ) tract in the disease context. The exact biological function of atxn-3 is not fully understood, but it has been described that, when expanded atxn-3 undergoes a toxic gain-of-function that deregulates normal cellular pathways leading to neuronal loss. Recently, it has been suggested that abnormal CAG tracts in mRNA transcripts might also be toxic. As with other polyglutamine diseases, greater numbers of CAG repeats are associated with earlier ages of onset and more severe symptoms.Currently, no therapies capable of delaying or treating the disease are available, and MJD remains a fatal disorder. Many of the therapeutic strategies that have been tested act at a post-transcriptional level, being unable to prevent the putative toxicity of CAG expanded mRNA transcripts. Therefore, new strategies that act at a pre-transcriptional level may be advantageous.However, disease studies can only be robust and feasible when the adequate disease model is used. Yet, the available mouse models used to study MJD either fail to properly mimic the actual genetic context of the disease or are of limited use due to slow and mild symptom progression.In the last decade, the field of gene editing has been thriving. The use of the CRISPR/Cas9 system as a tool for gene editing brought the possibility of performing low-cost, flexible and easy genomic manipulation virtually at any loci. Moreover, CRISPR/Cas9 variants, such as the catalytic inactivated Cas9 (dCas9) have shown promising results regarding gene transcription regulation. In the first part of this work, we planned to establish an in vitro strategy to refine the yeast artificial chromosome (YAC) MJD-Q84.2 mouse, which is the MJD model that best recapitulates the symptoms and the genetic context of the human condition. In this work we proposed to use gene editing tools to overexpand the ATXN3 CAG tract in the exon 10, from 84 to 141 CAG; applying this strategy to the model would be expected to generate a robust mouse model that displayed a more severe phenotype and an earlier disease onset, comparing to the YAC MJD-Q84.2 model. However, the in vitro results here presented, using HEK 293T cells, showed that the strategy used was inefficient at overexpanding the CAG repeats.At the same time, a CRISPR/Cas9-based strategy for correcting the pathogenic ATXN3 gene that could be used to generate isogenic MJD patient-derived cell lines was also tested. The study here presented, using HEK 293T cells, showed that it is possible to integrate a DNA fragment containing 14 CAG repeats plus a selection cassette in the exon 10 of the ATXN3 gene. However, this strategy was not completely infallible, and integration seemed to be independent from Cas9 activity. In the second part of this work, we assessed the effects of dCas9-KRAB as a strategy to pre-transcriptionally silence mutant ATXN3 in a MJD mouse model. In vivo results showed that this approach has a therapeutic potential to improve motor performance in a severely-impaired transgenic mouse model of MJD.
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7224036669
